AOD-9604

AOD-9604 is a modified fragment of human growth hormone, specifically a 16-amino-acid peptide corresponding to the C-terminal region of hGH (residues 177–191), with an added tyrosine at position 1. Its molecular weight is 1815.08 Da. The compound emerged from research conducted primarily at Monash University in Australia during the 1990s, when scientists sought to identify which part of the growth hormone molecule was responsible for stimulating fat breakdown. The full hGH molecule had been known for decades to exert lipolytic effects, but clinical use for weight loss was complicated by its tendency to cause insulin resistance, promote unwanted tissue growth, and carry significant side effects. By isolating the fragment responsible for lipolysis, researchers hoped to create a safer, targeted anti-obesity agent.

Early animal studies showed that AOD-9604 reduced body fat in obese mice without producing the metabolic side effects linked to full hGH. This made it an attractive candidate for pharmaceutical development. The Australian company Metabolic Pharmaceuticals advanced the compound into human clinical trials during the early 2000s, testing it in overweight and obese adults. Phase IIb trials enrolled several hundred participants and evaluated multiple doses over 12 weeks, making AOD-9604 one of the more clinically tested peptides in the weight-management space.

Despite completing multiple phases of clinical evaluation, AOD-9604 did not demonstrate statistically significant weight loss compared to placebo in its pivotal Phase IIb trials, and the obesity drug development program was ultimately discontinued. However, interest in the compound has persisted for two reasons. First, its mechanism of action remains scientifically interesting for understanding how discrete fragments of hGH regulate lipid metabolism. Second, researchers have identified potential applications in musculoskeletal repair, particularly cartilage regeneration, shifting some attention toward orthopedic medicine. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons noted AOD-9604 among peptides being investigated for joint and tissue repair.

Because AOD-9604 does not appear to stimulate IGF-1 production or bind the growth hormone receptor in a way that influences standard anti-doping immunoassays for hGH isoforms, it has also attracted attention in sports doping research. A 2013 study published in Drug Testing and Analysis confirmed that AOD-9604 does not interfere with the World Anti-Doping Agency hGH isoform test, raising analytical challenges for anti-doping laboratories.

AOD-9604 exerts its primary biological effects through mechanisms distinct from those of intact human growth hormone. Full-length hGH produces its anabolic and lipolytic effects partly through binding to the growth hormone receptor (GHR), which activates the JAK2-STAT5 signaling cascade and ultimately stimulates IGF-1 production in the liver. AOD-9604 does not appear to bind the GHR with meaningful affinity, which explains why it does not produce the growth-promoting or insulin-desensitizing effects of the parent molecule.

Instead, the lipolytic activity of AOD-9604 is believed to involve direct interaction with adipose tissue through beta-adrenergic receptor pathways. Research in animal models suggests the peptide activates beta-3 adrenergic receptors on fat cells, stimulating adenylate cyclase activity and increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which in turn phosphorylates hormone-sensitive lipase (HSL). Activated HSL cleaves stored triglycerides into free fatty acids and glycerol, a process known as lipolysis. AOD-9604 also appears to inhibit lipogenesis, the formation of new fat, by suppressing the activity of fatty acid synthase (FAS) and related enzymes involved in de novo lipid synthesis.

Interestingly, the peptide does not appear to affect fasting blood glucose, insulin levels, or IGF-1 concentrations in study subjects, supporting the conclusion that its metabolic effects are compartmentalized to fat tissue rather than systemic endocrine signaling. This metabolic selectivity is one of the central reasons researchers found it worth studying as a weight-loss candidate.

In the context of musculoskeletal research, AOD-9604 has shown activity in cartilage tissue models that may involve transforming growth factor-beta (TGF-β) signaling and stimulation of chondrocyte proliferation and extracellular matrix production. A 2026 review in Sports Medicine noted animal and in vitro evidence suggesting the peptide may promote repair of articular cartilage, though the precise receptor targets and downstream signaling pathways in this context remain incompletely characterized. The dual profile of fat-regulatory and potentially tissue-regenerative activity makes AOD-9604 a compound of ongoing mechanistic interest.

The research record for AOD-9604 spans preclinical animal studies, several phases of human clinical trials for obesity, and more recent investigations into musculoskeletal applications. The most substantial body of evidence comes from work conducted in Australia between the late 1990s and mid-2000s, primarily by Metabolic Pharmaceuticals in collaboration with academic researchers.

In animal studies, AOD-9604 consistently reduced body fat in obese rodent models. Work published in the early 2000s demonstrated that the peptide decreased adipose tissue mass in diet-induced and genetically obese mice, with effects comparable in some measures to those of full hGH but without the associated hyperglycemia or IGF-1 elevation. These preclinical findings established the pharmacological rationale for human trials.

Human clinical development advanced through Phase I, Phase IIa, and Phase IIb trials. A 2004 review in Current Opinion in Investigational Drugs (PMID 15134286) summarized the metabolic pharmacology of AOD-9604 and its progression through early clinical phases, noting a favorable initial safety signal. The compound was administered orally in some formulations, which was notable given the general challenge of oral bioavailability for peptides. Phase IIb trials enrolled several hundred overweight and obese adults across multiple sites. Participants received doses ranging from 1 mg to 54 mg per day over 12 weeks. While some early phase signals suggested modest fat reduction, the larger Phase IIb studies did not demonstrate statistically significant weight loss versus placebo, and development for obesity was halted. The compound's trajectory was covered in pipeline reviews published in Current Opinion in Investigational Drugs in 2006 (PMID 16625817) and gateway-to-clinical-trials summaries published in Methods Find Exp Clin Pharmacol in 2003 and 2005 (PMIDs 14571286, 14685303, 15834452).

In anti-doping research, a 2013 study published in Drug Testing and Analysis (PMID 24124033) tested whether administration of AOD-9604 would trigger a positive result on the WADA hGH isoform immunoassay. The researchers found it did not, confirming that the peptide fragment is analytically distinct from intact hGH. This finding has implications for anti-doping testing because it means athletes using AOD-9604 would not be flagged by the standard hGH test. Related analytical challenges were discussed in a 2014 review in the Journal of Pharmaceutical and Biomedical Analysis (PMID 24906629) and a 2014 Expert Review of Proteomics article (PMID 25382550), both of which listed AOD-9604 among peptides posing detection challenges in doping controls.

More recent research has shifted toward orthopedic applications. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews (PMID 41490200) and a 2026 Sports Medicine review (PMID 41966639) both noted animal and in vitro evidence for AOD-9604's potential in cartilage repair, though human data in this area remain absent. The human obesity trial data represent the most complete clinical dataset available.

Human clinical trials for obesity tested AOD-9604 at oral doses ranging from 1 mg to 54 mg per day over 12-week periods. These doses were evaluated in Phase IIb trials conducted by Metabolic Pharmaceuticals and summarized in peer-reviewed pipeline reviews. No approved clinical dose exists, as the compound was never granted regulatory approval. Doses circulating in non-clinical contexts are not supported by completed efficacy or safety trials.

AOD-9604 has one of the more complete short-term human safety records among research peptides, owing to its progression through multiple phases of clinical trials. In Phase I and Phase IIa studies, the compound was generally well tolerated at the doses tested, with no serious adverse events attributed to the drug. Phase IIb trials involving hundreds of participants over 12 weeks reported a safety profile not meaningfully different from placebo, with no significant effects on fasting glucose, insulin, IGF-1, or standard hematological and biochemical markers. This metabolic neutrality was by design, as the peptide was engineered to avoid the insulin-resistance effects of full hGH.

The most notable safety finding is the absence of the side effects typically associated with exogenous growth hormone use, including edema, joint pain, carpal tunnel syndrome, and hyperglycemia. Because AOD-9604 does not appear to activate the GHR-JAK2-STAT5-IGF-1 axis, the theoretical risks tied to IGF-1 elevation, including promotion of cell proliferation in susceptible tissues, do not apply based on current evidence.

However, important gaps remain. The clinical trials were designed around a 12-week treatment window for obesity, meaning long-term safety data beyond three months in humans do not exist in the published literature. The trials also focused on an adult overweight and obese population; safety data for other demographics, including lean individuals or those with metabolic conditions, are not available from formal studies.

In the context of musculoskeletal research, no human safety studies have been completed for AOD-9604 in orthopedic applications. The 2026 Sports Medicine review (PMID 41966639) noted that while animal models showed no overt toxicity in joint tissue studies, human-equivalent safety data for this indication are absent.

Injectable formulations of AOD-9604, which circulate outside of clinical research settings, have not been evaluated in the same systematic way as the oral formulations studied in trials. Any safety conclusions drawn from oral clinical trial data do not automatically extend to injectable use. Researchers and clinicians should treat the compound as investigational, with a favorable but incomplete safety record.

AOD-9604 is not approved by any major regulatory agency, including the FDA or the European Medicines Agency. Its clinical development for obesity was discontinued after Phase IIb trials failed to show statistically significant weight loss, and no active obesity trials are registered as of the available published record. The compound has not completed the regulatory pathway in any indication.

Active research interest has shifted toward musculoskeletal and cartilage repair applications. Reviews published in 2026 in both the Journal of the American Academy of Orthopaedic Surgeons and Sports Medicine identified AOD-9604 as a peptide with preclinical evidence for cartilage regeneration, though no completed human trials in this area have been published. The compound also remains a subject of interest in anti-doping science, as its lack of detection by the WADA hGH isoform assay represents an ongoing analytical challenge.

Key gaps include the absence of long-term human safety data, no completed efficacy trials in any musculoskeletal indication, and limited mechanistic clarity for its cartilage-related effects. Future research, if pursued, would likely require new Phase I trials in an orthopedic patient population.